Bausch + Lomb Introduces SimplifEYE IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses

First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista®

- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced the introduction of the SimplifEYE™ intraocular lens (IOL) delivery system, which is available exclusively for the enVista ® MX60PL and the enVista ® toric MX60PT, the first preloaded toric IOL available in the United States .

"The use of preloaded IOLs can contribute to surgical efficiency and reduce the risks associated with handling," said Joe Gordon , U.S. president, Bausch + Lomb. "The introduction of the SimplifEYE IOL delivery system for enVista, one of the most prominent brands in our surgical portfolio, is the latest example of our continued commitment to delivering innovations that meet the evolving needs of our customers."

The SimplifEYE injector facilitates smooth and consistent implantation of enVista lenses in just three steps through an incision as small as 2.2mm. The fully enclosed SnapSet™ cartridge houses an untouched IOL to ensure proper positioning and helps reduce the risk of lens damage. The beveled tip of the SimplifEYE system permits consistent lens folding to afford surgeons reproducible and reliable delivery of the enVista IOL.

"In my experience, this new delivery system allows for streamlined IOL insertion, and the lens then unfolds quickly, both of which contribute substantially to enhancing efficiency in my OR," said Dee Stephenson, M.D., from Stephenson Eye Associates in Venice, Florida and first surgeon to use the SimplifEYE system to implant an MX60PT. "I look forward to having continued access to these advantages while also offering patients the many benefits that the enVista platform offers."

The enVista MX60PL offers the widest range of powers of any preloaded IOL (0-34D). The enVista toric (MX60PT) offers exceptional rotational stability as well as the lowest cylinder power of 1.25D, which allows surgeons to correct more of their astigmatic patients. Both preloaded lenses also offer the benefits of a zero spherical aberration (SA) optic with excellent focus tolerance and contrast sensitivity as well as StableFlex™ technology, which provides improved material properties to deliver more rapid unfolding and enhanced optic recovery following delivery. Because both lenses are uniform power center-to-edge, neither are affected by tilt and decentration.

For details about enVista lenses, indications and important safety information, please click here .

About enVista ® IOLs
The enVista® family of lenses, which include monofocal and toric IOLs, remain the only single-piece, hydrophobic acrylic lenses domestically available that have been proven to be glistening-free. 1 They feature a unique set of attributes that help compensate for the eye's natural imperfections. The Trusight™ aspheric optic provides the benefits of excellent image quality as well the potential for increased resistance to scratches and abrasions that may occur during loading and surgical manipulation. Step-vaulted AccuSet™ haptics allow for extensive interaction with the capsular bag to aid in securing the lens position. The SureEdge™ design features a continuous 360-degree square edge; similar square edge designs have been shown to have the potential to prevent posterior capsular opacification compared to round edge designs. 2,3,4

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

1.

Bausch + Lomb. enVista® Toric IOL DFU

2.

Nishi O et al. J Cataract Refract Surg. 2004;30:2170-2176.

3.

Nixon DR et al. J Cataract Refract Surg. 2010;36:929-934.

4.

Buehl, Wolf and Findl, Oliver. "Effect of Intraocular Lens Design on Posterior Capsule Opacification." J Cataract Refractive Surgery, 2008; 34: 1976-1985.

® /tm are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.
EVA.0032.USA.20

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)


Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch--lomb-introduces-simplifeye-iol-delivery-system-for-envista-toric-and-monofocal-preloaded-intraocular-lenses-301160139.html

SOURCE Bausch Health Companies Inc.

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

  • New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon delivery
  • AVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies ("CRT") 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic ("PK") data on Virtue ® Sirolimus AngioInfusion Balloon ("SAB"), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New real-world data shows MiniMed 780G system sustains strong global performance, exceeding international targets for diabetes management

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures

Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States . The data was presented at the 17 th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy . These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for fourth quarter of fiscal year 2024

Board authorizes $5 billion for share repurchases

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024 approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on April 12, 2024 to shareholders of record at the close of business on March 22, 2024 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×